Abivax Announces Closing of Upsized $920 Million Public Offering
New York – July 6, 2026
Cooley advised Abivax SA (Euronext Paris: FR0012333284 – ABVX, Nasdaq: ABVX), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, on its underwritten public offering of 7,360,000 American Depositary Shares (ADSs), each representing one ordinary share, €0.01 nominal value per share, of the company, at a public offering price of $125.00 per ADS. The aggregate gross proceeds from the offering were $920 million (€807.4 million), before deducting underwriting commissions and other offering expenses payable by the company, and includes the full exercise of the underwriters’ option to purchase additional 960,000 ADSs.
Lawyers Div Gupta, Minkyu Park, Ryan Sansom, David Brinton, Melanie Simon-Giblin, Camille Awono and Chelsea Braun led the Cooley team advising Abivax. The team also included debt finance lawyers Mischi a Marca, Jason Savich, Timothy Nguyen, Yoni Horn and Stevie Yu; tax lawyers Timothy Shapiro, Xander Lee, Calvin Lee and Rick Jantz; life sciences and healthcare regulatory lawyer Natasha Leskovsek; and cybersecurity lawyer Randy Sabett. Francis Wheeler provided opinion committee review.
Cooley previously advised Abivax on its $700+ million follow-on offering in July 2025 and on its $235.8 million initial public offering in October 2023.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related Contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.